Colleges
Research groups
Jack Tan
DPhil, BSc (Hons)
Group Leader/ Career Development Fellow
I am Group Leader/ Career Development Fellow at the Chinese Academy of Medical Sciences-Oxford Institute. My research focuses on developing next generation nanoparticle vaccines mainly against infectious diseases. I am also trying to understand immune responses elicited by nanoparticle based vaccines to help inform vaccine design. I am also a Project Manager on a CEPI-funded project to develop a pan-sarbecovirus (SARS-like betacoronaviruses) vaccine in which we are currently in preparation for a first in human trial. I am also a Fellow by Special Election at St Edmund Hall.
Key publications
-
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
Journal article
Tan TK. et al, (2021), Nat Commun, 12
Recent publications
-
Single-cycle influenza virus vaccine generates lung CD8+ Trm that cross-react against viral variants and subvert virus escape mutants.
Journal article
Zheng MZM. et al, (2023), Sci Adv, 9
-
The molecular reach of antibodies determines their SARS-CoV-2 neutralisation potency
Preprint
Huhn A. et al, (2023)
-
Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive Vaccinology.
Journal article
Hills RA. et al, (2023), bioRxiv
-
Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.
Journal article
Huang K-YA. et al, (2023), Nat Commun, 14
-
Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8+ T Cells in the Face of Pre-Existing Humoral Immunity.
Journal article
Zheng MZM. et al, (2022), J Immunol, 209, 1832 - 1836
-
Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8+ T Cells in the Face of Pre-Existing Humoral Immunity.
Journal article
Zheng MZM. et al, (2022), J Immunol
-
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.
Journal article
Cohen AA. et al, (2022), Science, 377
-
Pathogen-sugar interactions revealed by universal saturation transfer analysis.
Journal article
Buchanan CJ. et al, (2022), Science, 377
-
SpySwitch enables pH- or heat-responsive capture and release for plug-and-display nanoassembly.
Journal article
Vester SK. et al, (2022), Nat Commun, 13
-
Immune responses to Sinopharm/BBIBP-CorV in individuals in Sri Lanka.
Journal article
Jeewandara C. et al, (2022), Immunology
-
Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222.
Journal article
Jayathilaka D. et al, (2022), Clin Exp Immunol, 208, 323 - 331
-
Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine.
Journal article
Jeewandara C. et al, (2022), Immun Inflamm Dis, 10
-
Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites.
Journal article
MacLean AJ. et al, (2022), Immunity, 55, 718 - 733.e8
-
Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals.
Journal article
Jeewandara C. et al, (2022), Immun Inflamm Dis, 10
-
Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models.
Journal article
Cohen AA. et al, (2022), bioRxiv
-
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Journal article
Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15
-
Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac).
Journal article
Jeewandara C. et al, (2022), Sci Rep, 12
-
A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern.
Journal article
Ertesvåg NU. et al, (2022), Commun Med (Lond), 2
-
An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease.
Journal article
Peng Y. et al, (2022), Nat Immunol, 23, 50 - 61
-
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
Journal article
Huang K-YA. et al, (2022), Theranostics, 12, 1 - 17